4.6 Review

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms

Journal

TRENDS IN NEUROSCIENCES
Volume 42, Issue 3, Pages 205-220

Publisher

CELL PRESS
DOI: 10.1016/j.tins.2018.12.004

Keywords

-

Categories

Funding

  1. Wellcome trust [200102/Z/15/Z, 094849/Z/10/Z]
  2. Medical Research Council-UK [MC-A656-5QD30]
  3. Maudsley Charity [666]
  4. Brain and Behavior Research Foundation
  5. National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
  6. King's College London
  7. Wellcome Trust [200102/Z/15/Z] Funding Source: Wellcome Trust
  8. MRC [MC_U120097115] Funding Source: UKRI

Ask authors/readers for more resources

The mesolimbic hypothesis has been a central dogma of schizophrenia for decades, positing that aberrant functioning of midbrain dopamine projections to limbic regions causes psychotic symptoms. Recently, however, advances in neuroimaging techniques have led to the unanticipated finding that dopaminergic dysfunction in schizophrenia is greatest within nigrostriatal pathways, implicating the dorsal striatum in the pathophysiology and calling into question the mesolimbic theory. At the same time our knowledge of striatal anatomy and function has progressed, suggesting new mechanisms via which striatal dysfunction may contribute to the symptoms of schizophrenia. This Review draws together these developments, to explore what they mean for our understanding of the pathophysiology, clinical manifestations, and treatment of the disorder.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available